Article Figures & Data
Figures
- Figure 1.
Expression of the cellular receptor of AMLV and GALV in OC cells. Total RNA was extracted from non-malignant human cell lines (HEK293, fibroblasts) and human OC cell lines (Caov-3, A2780, RMG-1, and SKOV3). The RNA samples were prepared in triplicate, reverse-transcribed, and amplified using PCR with RRV-specific primers for PiT-2 (AMLV receptor), PiT-1 (GALV receptor), and GAPDH. GAPDH was used as an internal control to normalize for different amounts of total RNA.
- Figure 2.
Replication kinetics of AMLV and GALV vectors in human OC cells. Human fibroblasts and OC cells (A2780, Caov-3, RMG-1, and SKOV3) were inoculated with AMLV-GFP or GALV-GFP vectors at an MOI of 0.01. On the days of passage, cells were analyzed for GFP expression using flow cytometry. Representative data of three independent experiments are shown.
- Figure 3.
Prodrug activator gene-mediated cell killing effect after AMLV and GALV infection in vitro. Caov-3, A2780, RMG-1, and SKOV3 cells were inoculated with GALV-CD or AMLV-CD at an MOI of 0.01 on Day 1, and exposed to different concentrations of the 5-FC prodrug from Day 16 for four days. On Day 19, cell viability was examined using the AlamarBlue assay. The data are means and SDs from experiments performed in triplicate.
- Figure 4.
Antitumor effect of RRV-mediated prodrug activator gene therapy in an OC subcutaneous tumor model. Human OC xenografts were established in nude mice by subcutaneous inoculation of 1×106 SKOV3 cells into the right dorsal flank. When the tumor diameter reached 5 mm, tumors were injected with 2×104 TU (100 μl) of either AMLV-CD (n=13 per group) or GALV-CD (n=12) vector, or PBS (100 μl) (n=12). From Day 11 onwards, the mice received 5-FC three times a week. The data are presented as the means and SEs. *p<0.05 (each RRV-treated group vs. PBS group).
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.